Tag : LENVATINIB

CONFERENCE UPDATE

Lenvatinib + pembrolizumab delivers sustained efficacy in aRCC regardless of baseline bone metastases: Final analysis from CLEAR
Bone metastases occur in approximately one-third of patients with advanced renal cell carcinoma and are associated with poor prognosis. This is partly due to RCC-driven immune dysregulation and the release of factors such as fibroblast growth factor and platelet-derived growth factor that promote osteoclast activation and bone resorption.

Professor Camillo Porta

Chairman, Department of Oncology, University of Bari Aldo Moro & Policlinico Consorziale, Bari, Italy